Patents by Inventor Mi-Yeon Jang
Mi-Yeon Jang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109858Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.Type: ApplicationFiled: March 23, 2022Publication date: April 4, 2024Applicants: LG Chem, Ltd., LG Energy Solution, Ltd.Inventors: Jung Keun Kim, Su Jeong Kim, Mi Sook Lee, Won Kyun Lee, Duk Hun Jang, Jeong Ae Yoon, Kyoung Hoon Kim, Chul Haeng Lee, Mi Yeon Oh, Kil Sun Lee, Jung Min Lee, Esder Kang, Chan Woo Noh, Chul Eun Yeom
-
Publication number: 20240067686Abstract: The present invention relates to a novel peptide capable of inhibiting TGF-? signaling and the use thereof. The peptide of the present invention is capable of inhibiting the TGF-?-induced signaling pathway or the expression of TGF-?, and thus can treat or prevent various diseases caused by TGF-? signaling, and furthermore, can effectively inhibit tumorigenesis processes such as TGF-?-signaling induced tumor growth and metastasis.Type: ApplicationFiled: December 22, 2021Publication date: February 29, 2024Applicant: Korea Institute of Science and TechnologyInventors: Mi-Hue JANG, Chae-Min YUK, Ga-Yeon GO, Young-Eun LEE, Sang-Chul SHIN
-
Publication number: 20230002353Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: ApplicationFiled: December 30, 2020Publication date: January 5, 2023Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
-
Publication number: 20210371398Abstract: Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: December 30, 2020Publication date: December 2, 2021Inventors: Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taeyoung YOON, Mi Yeon JANG
-
Patent number: 10947215Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: GrantFiled: September 25, 2018Date of Patent: March 16, 2021Assignee: Dong-A Socio Holdings Co., Ltd.Inventors: Myeong-Seop Kim, Sumin Kim, Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taesun Park, Joon-Ho Sheen, Taeyoung Yoon, Mi Yeon Jang
-
Patent number: 10913730Abstract: Compounds of formula (I) and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: GrantFiled: October 9, 2017Date of Patent: February 9, 2021Assignee: Dong-A Socio Holdings Co., Ltd.Inventors: Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taeyoung Yoon, Mi Yeon Jang
-
Publication number: 20190315716Abstract: Compounds of formula (I) and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.Type: ApplicationFiled: October 9, 2017Publication date: October 17, 2019Inventors: Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taeyoung YOON, Mi Yeon JANG
-
Publication number: 20190119252Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: ApplicationFiled: September 25, 2018Publication date: April 25, 2019Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
-
Patent number: 10125118Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: GrantFiled: August 31, 2016Date of Patent: November 13, 2018Assignee: Dong-A Socio Holdings Co., Ltd.Inventors: Myeong-Seop Kim, Sumin Kim, Jin Kwan Kim, Hadong Kim, Ki Moon Ryu, Seong Jin Park, Taesun Park, Joon-Ho Sheen, Taeyoung Yoon, Mi Yeon Jang
-
Publication number: 20170355690Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: ApplicationFiled: August 31, 2016Publication date: December 14, 2017Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
-
Publication number: 20170066742Abstract: The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.Type: ApplicationFiled: August 31, 2016Publication date: March 9, 2017Inventors: Myeong-Seop KIM, Sumin KIM, Jin Kwan KIM, Hadong KIM, Ki Moon RYU, Seong Jin PARK, Taesun PARK, Joon-Ho SHEEN, Taeyoung YOON, Mi Yeon JANG
-
Patent number: 9221822Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.Type: GrantFiled: October 20, 2014Date of Patent: December 29, 2015Assignee: Katholieke Universiteit Leuven, K. U. Leuven R&DInventors: Piet Herdewijn, Steven De Jonghe, Ling-Jie Gao, Mi-Yeon Jang, Bart Vanderhoydonck, Mark Jozef Albert Waer, Yuan Lin, Jean Ferdinand Herman, Thierry Andre Michel Louat
-
Publication number: 20150038494Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Piet Herdewijn, Steven De Jonghe, Ling-Jie Gao, Mi-Yeon Jang, Bart Vanderhoydonck, Mark Jozef Albert Waer, Yuan Lin, Jean Ferdinand Herman, Thierry Andre Michel Louat
-
Patent number: 8901132Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.Type: GrantFiled: March 15, 2010Date of Patent: December 2, 2014Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Piet Herdewijn, Steven De Jonghe, Ling-Jie Gao, Mi-Yeon Jang, Bart Vanderhoydonck, Mark Jozef Albert Waer, Yuan Lin, Jean Ferdinand Herman, Thierry Andre Michel Louat
-
Publication number: 20120046278Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.Type: ApplicationFiled: March 15, 2010Publication date: February 23, 2012Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&DInventors: Piet Herdewijn, Steven De Jonghe, Ling-Jie Gao, Mi-Yeon Jang, Bart Vanderhoydonck, Mark Jozef Albert Waer, Yuan Lin, Jean Ferdinand Herman, Thierry Andre Michel Louat